文献速递腹部CT

新辅助放化疗后CT是否高估胰腺导管腺癌患者的胰外神经周围侵犯?

Does CT overestimate extra-pancreatic perineural invasion in patients with pancreatic ductal adenocarcinoma following neoadjuvant chemoradiation therapy?
PubMed 文献 · Br J Radiol · 2024-01-01

回顾性纳入123例接受根治性手术及胰腺方案CT评估可切除性的胰腺导管腺癌患者,其中97例接受新辅助放化疗;CT评估胰外神经周围侵犯的敏感度、特异度和AUC在全部患者为98%、30%、0.62,在新辅助放化疗患者为97%、22%、0.59,在未接受新辅助放化疗患者为100%、100%、1.00。结论认为胰腺方案CT在初治患者中诊断效能更好,新辅助放化疗患者中可能出现高估。

要点

  • 胰腺方案CT评估胰外神经周围侵犯在初治患者中表现优异。
  • 新辅助放化疗患者中CT评估胰外神经周围侵犯特异度低,易高估。
  • 假阳性评估发生于23%患者(28/123),且全部接受过新辅助放化疗。

核心结论

  • 胰腺方案CT在初治胰腺导管腺癌患者中诊断胰外神经周围侵犯的效能优于接受新辅助放化疗者,后者可能出现高估。

研究设计与样本

  • 回顾性研究纳入123例胰腺导管腺癌患者(66例男性,中位年龄66岁),于2011年9月至2019年3月期间接受根治性手术及胰腺方案CT评估手术可切除性;其中97例接受新辅助放化疗;两名放射科医生采用5分制量表(5=肯定存在,4=可能存在,3=不确定,2=可能不存在,1=肯定不存在)评估胰外神经周围侵犯。

诊断标准与关键数值

  • CT评估胰外神经周围侵犯的敏感度、特异度、AUC分别为:全部患者98%、30%、0.62;新辅助放化疗患者97%、22%、0.59;未接受新辅助放化疗患者100%、100%、1.00。

临床应用与阅片要点

  • 胰腺方案CT评估胰外神经周围侵犯时,需注意新辅助放化疗患者中假阳性率高,可能高估侵犯范围。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the diagnostic performance of CT in the assessment of extra-pancreatic perineural invasion (EPNI) in patients with pancreatic ductal adenocarcinoma (PDAC).

METHODS: This retrospective study included 123 patients (66 men; median age, 66 years) with PDAC who underwent radical surgery and pancreatic protocol CT for assessing surgical resectability between September 2011 and March 2019. Among the 123 patients, 97 patients had received neoadjuvant chemoradiation therapy (CRT). Two radiologists reviewed the CT images for evidence of EPNI using a 5-point scale (5 = definitely present, 4 = probably present, 3 = equivocally present, 2 = probably absent, and 1 = definitely absent). Diagnostic performance for assessing EPNI was evaluated with receiver operating characteristic (ROC) curve analysis.

RESULTS: The sensitivity, specificity, and area under the ROC curve for assessing EPNI were 98%, 30%, and 0.62 in all patients; 97%, 22%, and 0.59 in patients with neoadjuvant CRT; and 100%, 100%, and 1.00 in patients without neoadjuvant CRT, respectively. False-positive assessment of EPNI occurred in 23% of patients (n = 28/123), and 100% of these (n = 28/28) had received neoadjuvant CRT. There was moderate to substantial agreement between the readers (ĸ = 0.49-0.62).

CONCLUSION: Pancreatic protocol CT has better diagnostic performance for determination of EPNI in treatment naïve patients with PDAC and overestimation of EPNI is likely in patients who have received preoperative CRT.

ADVANCES IN KNOWLEDGE: Pancreatic protocol CT has better diagnostic performance for the detection of EPNI in treatment naïve patients compared to patients receiving neoadjuvant CRT.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Noda Y, Pisuchpen N, Parakh A, et al. Does CT overestimate extra-pancreatic perineural invasion in patients with pancreatic ductal adenocarcinoma following neoadjuvant chemoradiation therapy? Br J Radiol. 2024. PMID: 38305574. doi:10.1093/bjr/tqae001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。